Ligand Pharmaceuticals (LGND) on the Upswing: AI Predicts 4% Monthly Growth despite Bearish Signals
Despite recent bearish indicators, Ligand Pharmaceuticals (LGND, $71.7) has shown resilience and is forecasted to grow by 4% to $74.57 or more within the next month. Our trusty AI advisor, after considering numerous scenarios where the stock trended up over the month, puts the odds of this uptrend continuation at a promising 76%.
Discover the revolutionary potential of AI-driven trading decisions with Tickeron's advanced technology.
This outlook comes amidst challenging circumstances. The biotechnology industry, in which Ligand operates, shows an average market capitalization of 2.08B. Across the sector, market caps range from a modest 402 (PNEXF) to a whopping 345.46B (NONOF). Despite this vast disparity, Ligand has managed to hold its ground and show potential for growth.
Over the past week, the biotech sector exhibited a price growth of -3%. Looking further into the past, monthly price growth averaged 1%, while the quarterly growth reached 30%. The sector saw considerable volatility, with AGLE showcasing the highest price growth at an impressive 257% and AVTX experiencing the sharpest fall at -89%.
Furthermore, the volume growth in the industry has been dipping with weekly, monthly, and quarterly growth rates of -30%, -15%, and -75% respectively. Despite this overall reduction in trading activity, Ligand continues to make strides.
However, it's worth noting that LGND has seen a downward trend recently, with its 10-day moving average moving below the 50-day moving average on June 28, 2023. This crossover, typically considered a bearish signal, indicates that the trend may have shifted downwards. In previous instances where the 10-day average crossed below the 50-day, the stock continued to move higher over the following month in 13 out of 14 cases.
Although this suggests a 90% chance of a continued downward trend, the resilience and positive growth prediction for Ligand provide a compelling counter-narrative. Ligand Pharmaceuticals' ability to defy odds and expectations sets it apart, making it a stock to watch closely in the coming weeks.
Stay tuned as we continue to monitor these market movements and provide timely insights to help guide your investment decisions. At Tickeron, we believe in unleashing the power of artificial intelligence to enhance trading decisions, and our marketing team plays a pivotal role in sharing this vision with the world
LGND in downward trend: 10-day moving average moved below 50-day moving average on August 19, 2026
The 10-day moving average for LGND crossed bearishly below the 50-day moving average on August 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LGND as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
LGND moved below its 50-day moving average on August 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGND declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for LGND entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LGND advanced for three days, in of 344 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LGND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.900) is normal, around the industry mean (20.143). P/E Ratio (29.496) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (21.142) is also within normal values, averaging (444.692).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company
Industry Biotechnology
Advertisement